ArticleBiomolecules & biomedicine2026
CT-derived body composition as a predictor of supervised exercise therapy response in intermittent claudication and peripheral arterial disease: COMPOSE-PAD study protocol.
Article in Biomolecules & biomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07433309 (CT Body Composition Predicts Supervised Exercise Response in Peripheral Arterial Disease), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
CT Body Composition Predicts Supervised Exercise Response in Peripheral Arterial Disease: A Protocol
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peripheral arterial disease (PAD) commonly presents with intermittent claudication, for which supervised exercise therapy (SET) is recommended as first-line treatment; however, real-world SET non-completion is frequent and a clinically relevant subgroup of patients fails to achieve meaningful functional improvement. No validated pre-treatment tool currently identifies these likely non-responders. This protocol describes a prospective single-centre observational cohort study designed to determine whether body composition derived opportunistically from routine computed tomography angiography (CTA) at the third lumbar vertebral level (L3), specifically skeletal muscle density and visceral adipose tissue (VAT) area, independently predicts 3-month SET outcome in patients with Fontaine IIa-IIb intermittent claudication. A total of 128 consecutive patients will be enrolled at the Complex Cardiovascular Centre, Hospital AGEL Trinec-Podlesi, Czech Republic. The primary composite outcome is treatment success at 3 months, defined as both functional improvement on standardised treadmill testing, expressed as an absolute increase of at least 50 m or a relative increase of at least 50% in maximum walking distance (MWD), and freedom from revascularisation. Treatment failure includes SET non-completion, functional non-response among programme completers, or revascularisation during follow-up irrespective of functional result. Associations between skeletal muscle density, VAT area, and treatment outcome will be examined using prespecified multivariable logistic regression adjusted for age, sex, and baseline MWD, with bootstrap internal validation. As this is a study protocol, no outcome data are yet available; enrolment is planned to begin in June 2026. This study will assess whether zero-burden metabolic phenotyping from routine CTA can help identify patients less likely to benefit from conservative management alone, but any derived model will require external multicentre validation before clinical use. ClinicalTrials.gov: NCT07433309.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.